Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arcturus Therapeutics stock

Learn how to easily invest in Arcturus Therapeutics stock.

Arcturus Therapeutics is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 177 staff and has a trailing 12-month revenue of around $51.5 million.

How to buy Arcturus Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ARCT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Arcturus Therapeutics stock price (NASDAQ: ARCT)

Use our graph to track the performance of ARCT stocks over time.

Arcturus Therapeutics shares at a glance

Information last updated 2023-02-01.
Latest market close$21.24
52-week range$11.70 - $31.41
50-day moving average $17.97
200-day moving average $17.54
Wall St. target price$43.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-7.53

Buy Arcturus Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Arcturus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcturus Therapeutics price performance over time

Historical closes compared with the close of $21.24 from 2023-02-06

1 week (2023-01-31) 0.52%
1 month (2023-01-06) 29.43%
3 months (2022-11-08) -6.92%
6 months (2022-08-08) 1.05%
1 year (2022-02-08) -15.31%
2 years (2021-02-08) -75.56%
3 years (2020-02-07) 76.56%
5 years (2018-02-07) 231.88%

Arcturus Therapeutics financials

Revenue TTM $51.5 million
Gross profit TTM $12.4 million
Return on assets TTM -25.22%
Return on equity TTM -72.46%
Profit margin -284.78%
Book value $5.50
Market capitalisation $585.3 million

TTM: trailing 12 months

Arcturus Therapeutics share dividends

We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.

Have Arcturus Therapeutics's shares ever split?

Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.

Arcturus Therapeutics share price volatility

Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $11.7 up to $31.41. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.5563. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arcturus Therapeutics overview

Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company's pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U. S.

Frequently asked questions

What percentage of Arcturus Therapeutics is owned by insiders or institutions?
Currently 13.861% of Arcturus Therapeutics shares are held by insiders and 79.295% by institutions.
How many people work for Arcturus Therapeutics?
Latest data suggests 177 work at Arcturus Therapeutics.
When does the fiscal year end for Arcturus Therapeutics?
Arcturus Therapeutics's fiscal year ends in December.
Where is Arcturus Therapeutics based?
Arcturus Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121
What is Arcturus Therapeutics's ISIN number?
Arcturus Therapeutics's international securities identification number is: US03969T1097
What is Arcturus Therapeutics's CUSIP number?
Arcturus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03969T109

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site